Novartis AG ADR (NVS)vsTG Therapeutics Inc (TGTX)
NVS
Novartis AG ADR
$148.38
-0.17%
HEALTHCARE · Cap: $289.19B
TGTX
TG Therapeutics Inc
$53.94
-0.99%
HEALTHCARE · Cap: $7.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7979% more annual revenue ($56.58B vs $700.35M). TGTX leads profitability with a 65.9% profit margin vs 23.9%. TGTX appears more attractively valued with a PEG of 1.61. TGTX earns a higher WallStSmart Score of 70/100 (B-).
NVS
Hold49
out of 100
Grade: D+
TGTX
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.6%
Fair Value
$91.58
Current Price
$148.38
$56.80 premium
Intrinsic value data unavailable for TGTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Every $100 of equity generates 79 in profit
Keeps 66 of every $100 in revenue as profit
Revenue surging 69.6% year-over-year
Earnings expanding 300.0% YoY
Attractively priced relative to earnings
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Expensive relative to growth rate
Trading at 13.1x book value
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 65.9% and operating margin at 17.0%. Revenue growth of 69.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Debt/Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.68 — expect wider price swings.
TGTX is growing revenue faster at 69.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (70/100 vs 49/100), backed by strong 65.9% margins and 69.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?